Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brukinsa
Pharma
Trial results show value of Lilly's Jaypirca in front-line CLL
By nailing the primary endpoint in a trial of Jaypirca, Eli Lilly has brought the drug closer to becoming available to a broader group of patients.
Kevin Dunleavy
Sep 8, 2025 11:37am
BeOne widens BTK lead over AstraZeneca
Aug 6, 2025 10:55am
BeiGene's Brukinsa surpasses AZ’s Calquence in quarterly sales
Feb 27, 2025 10:56am
Should BeiGene or Legend sell itself in 2025?
Jan 9, 2025 9:15am
BeiGene pushes biomarker testing before treatment for CLL
Dec 4, 2024 6:00am
BeiGene defends Brukinsa from MSN's generic threat until 2037
Nov 19, 2024 3:55pm
